Fair commentary from a non-holder. Beats the usual garbage spewed by other non-holders.
CPH is only really beginning it's journey this year, with sophisticated/institutional investors John Hancock, S3, L1 Global Master supporting at 19c and committed to the journey. The psychedelics expansion in mental health treatment is an excellent opportunity, provided the phase 2 and 3 trials go well but on the cannabis front - I agree far more revenue is needed to justify the current market cap.
US reform will be the catalyst needed for CPH expansion and profitability I reckon.
Agree that the paid ads are high, but I'd like to see more aggressive marketing ahead of the OTC listing coming up in the next 2-3 weeks. Will have to wait and see how the US market rates the SP in the coming weeks.
- Forums
- ASX - By Stock
- CPH
- Ann: Mernova Awarded Craft Designation with OCS
Ann: Mernova Awarded Craft Designation with OCS, page-39
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online